BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progress

BETTA PHARMACEUTICALS disclosed the progress of the clinical research on the postoperative adjuvant indication of ensartinib on the morning of August 25: In April 2022, the clinical trial for the hydrochloride capsule of ensartinib, submitted by the company for postoperative adjuvant treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer, was approved by the National Medical Products Administration. Recently, an independent data monitoring committee evaluated the clinical trial, and the interim analysis showed positive results, achieving the primary endpoint set for the study, with significant statistical significance and important clinical benefits. Detailed data from the study will be announced at a major international academic conference this year. The company's team is intensifying preparations for the submission materials to expedite the NDA application for the new indication